Literature DB >> 32298240

Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia.

Joshua R Huot1,2, Leah J Novinger3, Fabrizio Pin2, Ashok Narasimhan1, Teresa A Zimmers1,2,4,5, Thomas M O'Connell2,3,4,5, Andrea Bonetto1,2,3,4,5.   

Abstract

Advanced colorectal cancer (CRC) is often accompanied by development of liver metastases (LMs) and skeletal muscle wasting (i.e., cachexia). Despite plaguing the majority of CRC patients, cachexia remains unresolved. By using mice injected with Colon-26 mouse tumors, either subcutaneously (s.c.; C26) or intrasplenically to mimic hepatic dissemination of cancer cells (mC26), here we aimed to further characterize functional, molecular, and metabolic effects on skeletal muscle and examine whether LMs exacerbate CRC-induced cachexia. C26-derived LMs were associated with progressive loss of body weight, as well as with significant reductions in skeletal muscle size and strength, in line with reduced phosphorylation of markers of protein anabolism and enhanced protein catabolism. mC26 hosts showed prevalence of fibers with glycolytic metabolism and enhanced lipid accumulation, consistent with abnormalities of mitochondrial homeostasis and energy metabolism. In a comparison with mice bearing s.c. C26, cachexia appeared exacerbated in the mC26 hosts, as also supported by differentially expressed pathways within skeletal muscle. Overall, our model recapitulates the cachectic phenotype of metastatic CRC and reveals that formation of LMs resulting from CRC exacerbate cancer-induced skeletal muscle wasting by promoting differential gene expression signatures.

Entities:  

Keywords:  Cell Biology; Colorectal cancer; Cytokines; Muscle; Muscle Biology

Mesh:

Year:  2020        PMID: 32298240      PMCID: PMC7253026          DOI: 10.1172/jci.insight.136687

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  71 in total

1.  Assessment of muscle mass and strength in mice.

Authors:  Andrea Bonetto; Daniel C Andersson; David L Waning
Journal:  Bonekey Rep       Date:  2015-08-19

2.  NGSUtils: a software suite for analyzing and manipulating next-generation sequencing datasets.

Authors:  Marcus R Breese; Yunlong Liu
Journal:  Bioinformatics       Date:  2013-01-12       Impact factor: 6.937

Review 3.  Definition and classification of cancer cachexia: an international consensus.

Authors:  Kenneth Fearon; Florian Strasser; Stefan D Anker; Ingvar Bosaeus; Eduardo Bruera; Robin L Fainsinger; Aminah Jatoi; Charles Loprinzi; Neil MacDonald; Giovanni Mantovani; Mellar Davis; Maurizio Muscaritoli; Faith Ottery; Lukas Radbruch; Paula Ravasco; Declan Walsh; Andrew Wilcock; Stein Kaasa; Vickie E Baracos
Journal:  Lancet Oncol       Date:  2011-02-04       Impact factor: 41.316

4.  Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.

Authors:  Paola Aulino; Emanuele Berardi; Veronica M Cardillo; Emanuele Rizzuto; Barbara Perniconi; Carla Ramina; Fabrizio Padula; Enrico P Spugnini; Alfonso Baldi; Fabio Faiola; Sergio Adamo; Dario Coletti
Journal:  BMC Cancer       Date:  2010-07-08       Impact factor: 4.430

5.  Physiological characterization of a mouse model of cachexia in colorectal liver metastases.

Authors:  Kate T Murphy; Adam Struk; Cathy Malcontenti-Wilson; Christopher Christophi; Gordon S Lynch
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

6.  Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles.

Authors:  Hyun-Kyung Yu; Jang-Seong Kim; Ho-Jeong Lee; Jin-Hyung Ahn; Suk-Keun Lee; Soon-Won Hong; Yeup Yoon
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

7.  Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia.

Authors:  Keith S Kwak; Xiaolan Zhou; Vered Solomon; Vickie E Baracos; James Davis; Anthony W Bannon; William J Boyle; David L Lacey; H Q Han
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

8.  The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse.

Authors:  James P White; John W Baynes; Stephen L Welle; Matthew C Kostek; Lydia E Matesic; Shuichi Sato; James A Carson
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

9.  Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.

Authors:  Francesca Pretto; Carmen Ghilardi; Michele Moschetta; Andrea Bassi; Alessandra Rovida; Valentina Scarlato; Laura Talamini; Fabio Fiordaliso; Cinzia Bisighini; Giovanna Damia; Maria Rosa Bani; Rosanna Piccirillo; Raffaella Giavazzi
Journal:  Oncotarget       Date:  2015-02-20

10.  ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.

Authors:  Rafael Barreto; Yukiko Kitase; Tsutomu Matsumoto; Fabrizio Pin; Kyra C Colston; Katherine E Couch; Thomas M O'Connell; Marion E Couch; Lynda F Bonewald; Andrea Bonetto
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

View more
  8 in total

Review 1.  Nutrition challenges of cancer cachexia.

Authors:  Omnia U Gaafer; Teresa A Zimmers
Journal:  JPEN J Parenter Enteral Nutr       Date:  2021-11       Impact factor: 4.016

2.  RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice.

Authors:  Fabrizio Pin; Alexander J Jones; Joshua R Huot; Ashok Narasimhan; Teresa A Zimmers; Lynda F Bonewald; Andrea Bonetto
Journal:  J Bone Miner Res       Date:  2021-12-13       Impact factor: 6.390

3.  MC38 Tumors Induce Musculoskeletal Defects in Colorectal Cancer.

Authors:  Joshua R Huot; Fabrizio Pin; Alyson L Essex; Andrea Bonetto
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

Review 4.  Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments.

Authors:  Juha J Hulmi; Tuuli A Nissinen; Fabio Penna; Andrea Bonetto
Journal:  Cells       Date:  2021-02-28       Impact factor: 6.600

5.  GSI Treatment Preserves Protein Synthesis in C2C12 Myotubes.

Authors:  Joshua R Huot; Brian Thompson; Charlotte McMullen; Joseph S Marino; Susan T Arthur
Journal:  Cells       Date:  2021-07-15       Impact factor: 7.666

6.  The Mitochondria-Targeting Agent MitoQ Improves Muscle Atrophy, Weakness and Oxidative Metabolism in C26 Tumor-Bearing Mice.

Authors:  Fabrizio Pin; Joshua R Huot; Andrea Bonetto
Journal:  Front Cell Dev Biol       Date:  2022-03-22

Review 7.  Muscle and Bone Defects in Metastatic Disease.

Authors:  Martina Pauk; Hiroaki Saito; Eric Hesse; Hanna Taipaleenmäki
Journal:  Curr Osteoporos Rep       Date:  2022-08-22       Impact factor: 5.163

8.  Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity.

Authors:  Joshua R Huot; Fabrizio Pin; Andrea Bonetto
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.